Cargando…
Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice
SIMPLE SUMMARY: Cancer treatments are increasingly based on therapeutic antibodies to clear tumors. While in vivo mouse models are useful to predict effectiveness of human antibodies it is not completely clear how useful these models are to test antibodies engineered with enhanced effector functions...
Autores principales: | Braster, Rens, Bögels, Marijn, Benonisson, Hreinn, Wuhrer, Manfred, Plomp, Rosina, Bentlage, Arthur E. H., Korthouwer, Rianne, Visser, Remco, Verbeek, J. Sjef, van Egmond, Marjolein, Vidarsson, Gestur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156657/ https://www.ncbi.nlm.nih.gov/pubmed/34069226 http://dx.doi.org/10.3390/cancers13102372 |
Ejemplares similares
-
Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice
por: Braster, Rens, et al.
Publicado: (2017) -
Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afucosylated IgG for enhanced ADCC
por: Mao, Changchuin, et al.
Publicado: (2021) -
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans
por: Dekkers, Gillian, et al.
Publicado: (2016) -
Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells
por: Gruijs, Mandy, et al.
Publicado: (2022) -
Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies
por: Sonneveld, Myrthe E., et al.
Publicado: (2018)